Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT OMALIZUMAB FOR INJECTION OBTAINS MARKETING APPROVAL GRANTED BY NMPA

VOLUNTARY ANNOUNCEMENT OMALIZUMAB FOR INJECTION OBTAINS MARKETING APPROVAL GRANTED BY NMPA

October 08, 2024

VOLUNTARY ANNOUNCEMENT OMALIZUMAB FOR INJECTION OBTAINS MARKETING APPROVAL GRANTED BY NMPA

VOLUNTARY ANNOUNCEMENT OMALIZUMAB FOR INJECTION OBTAINS MARKETING APPROVAL GRANTED BY NMPA

Next: VOLUNTARY ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT FOR YS2302018 WITH ASTRAZENECA

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat